Edition:
India

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

81.13USD
1:30am IST
Change (% chg)

$-0.95 (-1.16%)
Prev Close
$82.08
Open
$82.91
Day's High
$83.30
Day's Low
$80.90
Volume
379,423
Avg. Vol
492,843
52-wk High
$100.50
52-wk Low
$75.84

Select another date:

BRIEF-Biomarin Pharma CEO's 2017 Compensation Was $15.9 Million

* BIOMARIN PHARMACEUTICAL INC SAYS CEO JEAN-JACQUES BIENAIMÉ'S 2017 TOTAL COMPENSATION WAS $15.9 MILLION VERSUS $16.9 MILLION IN 2016 – SEC FILING

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN'S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

* BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application

* BIOMARIN RECEIVES ANTICIPATED NOTIFICATION OF PDUFA EXTENSION FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION (BLA) TO MAY 28, 2018

BRIEF-Biomarin Doses First Patient In Late-Stage Trial Of Gene Therapy For Bleeding Disorder

* BIOMARIN DOSES FIRST PATIENT IN GLOBAL GENER8-1 PHASE 3 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A Source text for Eikon: Further company coverage:

BRIEF-Biomarin Sells Second Priority Review Voucher For $125 Mln

* BIOMARIN SELLS SECOND PRIORITY REVIEW VOUCHER FOR $125 MILLION

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

Select another date: